<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441882</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00006146</org_study_id>
    <secondary_id>NCI-2011-03136</secondary_id>
    <secondary_id>HEM 10010-L</secondary_id>
    <secondary_id>OHSU-6146</secondary_id>
    <secondary_id>BMS CA180-280</secondary_id>
    <secondary_id>IRB00006146</secondary_id>
    <nct_id>NCT01441882</nct_id>
  </id_info>
  <brief_title>Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well dasatinib works in treating patients with chronic&#xD;
      lymphocytic leukemia (CLL). Dasatinib may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the biologic target activity of dasatinib in CLL patients found to have&#xD;
      pre-treatment in vitro dasatinib cytotoxicity (as defined by a &gt;= 50% decrease in absolute&#xD;
      lymphocyte count and/or bone marrow CLL count and/or lymph node or spleen size).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate overall objective response rates per CLL National Cancer Institute (NCI)&#xD;
      working group.&#xD;
&#xD;
      II. To determine drug safety and tolerability of dasatinib in patients with CLL.&#xD;
&#xD;
      III. To determine overall (OS) and progression-free survival (PFS).&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC),&#xD;
      Bruton agammaglobulinemia tyrosine kinase (BTK), or tec protein tyrosine kinase (TEC) family&#xD;
      kinase inhibition correlates with clinical response.&#xD;
&#xD;
      II. To determine which prognostic subgroups (presence of &gt;= 1 of the following: 11q or 17p&#xD;
      deletion; cluster of differentiation [CD]38 or zeta-chain-associated protein kinase 70 [Zap&#xD;
      70] expression; unmutated immunoglobulin heavy chain [IgVH]) respond to dasatinib therapy.&#xD;
&#xD;
      III. To evaluate differences in baseline CLL gene expression between CLL samples that are&#xD;
      sensitive or in-sensitive to dasatinib.&#xD;
&#xD;
      IV. To analyze changes in CLL gene expression after dasatinib treatment. V. To evaluate&#xD;
      dasatinib pharmacokinetics. VI. To evaluate changes in type I receptor tyrosine kinase-like&#xD;
      orphan receptor (ROR-1) expression with dasatinib treatment.&#xD;
&#xD;
      VII. To correlate response to pre-clinical IC50 in the presence/absence of HS-5 conditioned&#xD;
      media.&#xD;
&#xD;
      VIII. To explore role of possible kinase mutations related to dasatinib response.&#xD;
&#xD;
      IX. To measure chemokines before and during treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive dasatinib orally (PO) once daily (QD) during course 1 and if tolerated,&#xD;
      twice daily (BID) in subsequent courses. Courses repeat every 4 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With In Vitro Dasatinib Sensitivity in Predicting Clinical Activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Defined by a decrease in absolute lymphocyte count, as determined by peripheral blood complete blood count (CBC) with differential or by bone marrow examination of 50 % and/or a decrease of detectable total lymph node size or spleen size by 50% (either by clinical examination contrast enhanced computed tomography [CT]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented. Complete Response (CR): present &gt;=2 mos: no symptoms of CLL, normal findings on exam, ALC &lt; 4.000/mm3, ANC &gt;1.500/ mm3, platelet (PLT) count (ct) &gt;100.000/ mm3, hemoglobin (Hgb) concentration &gt;11 g/dL (untransfused), bone marrow (BM) lymphocytosis &lt;30%, and no nodules (lymphoid aggregates) on BM biopsy. Partial Response (PR): present &gt;=2 months: a reduction in prev. enlarged nodes, spleen, &amp; liver by at least 50%. ANC &gt;= 1.500/ mm3 or PLT ct &gt;= 100.000/ mm3 or Hgb concentration &gt;=11 g/dL or 50% improvement over pre-therapy reductions in Hgb concentration and/or PLT ct. Nodular PR: persistent BM nodules or infiltrates seen on BM biopsy those achieving a CR or PR. Stable Disease (SD): Does not meet CR or PR, but also not progressive disease (PD). PD: 50% size increase of lymph node, spleen, liver; or histologic (e.g. Richter's) transformation (per NCI and iwCLL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate the survival curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate the survival curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (Number of Participants Affected)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessed According to the NCI Common Terminology Criteria for Adverse Events Version 4.0. Adverse events will be tabulated and summarized according to key reporting criteria (i.e., grade or seriousness, unanticipated, treatment attribution). Refer to the Adverse Event tables below for specific details.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent and Health Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization for release of personal information&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) =&lt; 2&#xD;
&#xD;
          -  In vitro dasatinib sensitivity (IC 50 =&lt; 50 nm per MTS assay)&#xD;
&#xD;
          -  Diagnosis of CLL and must meet one of the following:&#xD;
&#xD;
               -  Relapsed CLL in all patients who have failed at least one prior treatment,&#xD;
                  regardless of risk group&#xD;
&#xD;
               -  OR De novo (treatment-na√Øve) patients age &gt;= 65 who are not candidates for or do&#xD;
                  not want to pursue aggressive chemotherapy treatment&#xD;
&#xD;
          -  Have indications for treatment or evidence of progressive disease defined as follows&#xD;
             (1996 NCI working group):&#xD;
&#xD;
               -  Massive or progressive splenomegaly&#xD;
&#xD;
               -  Massive lymph nodes (&gt;= 10 cm), nodal clusters (&gt;= 10 cm), or progressive&#xD;
                  lymphadenopathy&#xD;
&#xD;
               -  Symptomatic anemia and/or thrombocytopenia (Rai stages III or IV disease)&#xD;
&#xD;
               -  Autoimmune hemolytic anemia and/or thrombocytopenia that are poorly responsive to&#xD;
                  corticosteroid therapy&#xD;
&#xD;
               -  Progressive lymphocytosis with increase in lymphocyte count of &gt;= 50% over a&#xD;
                  2-month period or an anticipated doubling time of &lt; 6 months&#xD;
&#xD;
               -  Repeated episodes of infection&#xD;
&#xD;
          -  Have not received CLL treatment within the past 2 weeks&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 x ULN&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 1.2&#xD;
&#xD;
          -  Platelet (Plt) count &gt; 30,000&#xD;
&#xD;
          -  Ability to take oral medication (dasatinib must be swallowed whole)&#xD;
&#xD;
          -  No clinically significant infections as determined by the investigator&#xD;
&#xD;
          -  Normal corrected QT (QTc) interval (&lt; 450 msec)&#xD;
&#xD;
          -  Serum potassium and magnesium are within normal limits&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (sensitivity =&lt; 25 IU HCG/L) within 72 hours prior to the start of study drug&#xD;
             administration&#xD;
&#xD;
          -  Persons of reproductive potential must agree to use an adequate method of&#xD;
             contraception throughout treatment and for at least 4 weeks after study drug is&#xD;
             stopped prior to study enrollment; women of childbearing potential must be advised of&#xD;
             the importance of avoiding pregnancy during trial participation and the potential risk&#xD;
             factors for an unintentional pregnancy&#xD;
&#xD;
          -  After consent, discontinuation (&quot;washout period&quot;) of any medications known to&#xD;
             contribute significantly to the risk of QT prolongation or interfere with cytochrome&#xD;
             P450, family 3, subfamily A, polypeptide 4 (CYP3A4) mediated drug metabolism&#xD;
&#xD;
          -  Patient agrees to discontinue St. John's Wort while receiving dasatinib therapy&#xD;
             (discontinue St. John's Wort at least 5 days before starting dasatinib)&#xD;
&#xD;
          -  Patient agrees that IV bisphosphonates will be withheld for the first eight weeks of&#xD;
             dasatinib therapy due to risk of hypocalcemia&#xD;
&#xD;
          -  Patient agrees to discontinue anti-coagulants and anti-platelet drugs; note: a low&#xD;
             dose aspirin regimen (81mg QD) is permitted with close monitoring of the subject's&#xD;
             platelets for a level &gt;= 50,000/mm^3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy&#xD;
&#xD;
          -  Pleural or pericardial effusion of any grade&#xD;
&#xD;
          -  Uncontrolled angina, &gt; New York Heart Association (NYHA) class III congestive heart&#xD;
             failure or myocardial infarction (MI) within 6 months prior to study enrollment&#xD;
&#xD;
          -  Diagnosed congenital long QT syndrome&#xD;
&#xD;
          -  Any history of clinically significant ventricular arrhythmias (such as ventricular&#xD;
             tachycardia, ventricular fibrillation, or Torsades de pointes)&#xD;
&#xD;
          -  Prolonged QTc interval on pre-entry electrocardiogram (&gt; 450 msec)&#xD;
&#xD;
          -  Subjects who are detained or imprisoned are not eligible&#xD;
&#xD;
          -  History of significant bleeding disorder unrelated to cancer, including:&#xD;
&#xD;
               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)&#xD;
&#xD;
               -  Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor&#xD;
                  VIII antibodies)&#xD;
&#xD;
          -  May not take concomitant medications that are generally accepted to have a risk of&#xD;
             causing Torsades de Pointes including: (patients must discontinue drug 7 days prior to&#xD;
             starting dasatinib)&#xD;
&#xD;
               -  Quinidine, procainamide, disopyramide&#xD;
&#xD;
               -  Amiodarone, sotalol, ibutilide, dofetilide&#xD;
&#xD;
               -  Erythromycin, clarithromycin&#xD;
&#xD;
               -  Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide&#xD;
&#xD;
               -  Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,&#xD;
                  halofantrine, levomethadyl, sparfloxacin, lidoflazine&#xD;
&#xD;
          -  Patients already taking other CYP inducers or inhibitors other than those listed above&#xD;
             are eligible for the study only after principal investigator (PI) review; dose&#xD;
             adjustments and/or monitoring of drug levels where applicable will be made as needed&#xD;
             by the PI after consultation with pharmacy&#xD;
&#xD;
          -  Women who:&#xD;
&#xD;
               -  Are unwilling or unable to use an acceptable method to avoid pregnancy for the&#xD;
                  entire study period and for at least 4 weeks after cessation of study drug, or&#xD;
&#xD;
               -  Have a positive pregnancy test at baseline, or&#xD;
&#xD;
               -  Are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Spurgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <results_first_submitted>July 11, 2017</results_first_submitted>
  <results_first_submitted_qc>January 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2018</results_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Stephen Spurgeon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Dasatinib)</title>
          <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Dasatinib)</title>
          <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With In Vitro Dasatinib Sensitivity in Predicting Clinical Activity</title>
        <description>Defined by a decrease in absolute lymphocyte count, as determined by peripheral blood complete blood count (CBC) with differential or by bone marrow examination of 50 % and/or a decrease of detectable total lymph node size or spleen size by 50% (either by clinical examination contrast enhanced computed tomography [CT]).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Dasatinib)</title>
            <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With In Vitro Dasatinib Sensitivity in Predicting Clinical Activity</title>
          <description>Defined by a decrease in absolute lymphocyte count, as determined by peripheral blood complete blood count (CBC) with differential or by bone marrow examination of 50 % and/or a decrease of detectable total lymph node size or spleen size by 50% (either by clinical examination contrast enhanced computed tomography [CT]).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>In vitro dasatinib sensitivity in predicting clini</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ABS lymph ct decrease &gt; 50%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Total lymph size decrease &gt; 50%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Spleen decrease by &gt; 50%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline in responders compared to non-responders (lymph node size).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-parametric two-sided Mann-Whitney test was run assuming non-Gaussian distributions. Two-tailed with 95% confidence intervals.</non_inferiority_desc>
            <p_value>0.0106</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Threshold for statistical significance is 0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline in responders compared to non-responders (Absolute Lymphocyte Count (ALC)).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-parametric two-sided Mann-Whitney test was run assuming non-Gaussian distributions. Two-tailed with 95% confidence intervals.</non_inferiority_desc>
            <p_value>0.19860</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Threshold for statistical significance is 0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline in responders compared to non-responders (spleen size).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-parametric two-sided Mann-Whitney test was run assuming non-Gaussian distributions. Two-tailed with 95% confidence intervals.</non_inferiority_desc>
            <p_value>0.5167</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Threshold for statistical significance is 0.05.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response</title>
        <description>Proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented. Complete Response (CR): present &gt;=2 mos: no symptoms of CLL, normal findings on exam, ALC &lt; 4.000/mm3, ANC &gt;1.500/ mm3, platelet (PLT) count (ct) &gt;100.000/ mm3, hemoglobin (Hgb) concentration &gt;11 g/dL (untransfused), bone marrow (BM) lymphocytosis &lt;30%, and no nodules (lymphoid aggregates) on BM biopsy. Partial Response (PR): present &gt;=2 months: a reduction in prev. enlarged nodes, spleen, &amp; liver by at least 50%. ANC &gt;= 1.500/ mm3 or PLT ct &gt;= 100.000/ mm3 or Hgb concentration &gt;=11 g/dL or 50% improvement over pre-therapy reductions in Hgb concentration and/or PLT ct. Nodular PR: persistent BM nodules or infiltrates seen on BM biopsy those achieving a CR or PR. Stable Disease (SD): Does not meet CR or PR, but also not progressive disease (PD). PD: 50% size increase of lymph node, spleen, liver; or histologic (e.g. Richter's) transformation (per NCI and iwCLL).</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Dasatinib)</title>
            <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response</title>
          <description>Proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented. Complete Response (CR): present &gt;=2 mos: no symptoms of CLL, normal findings on exam, ALC &lt; 4.000/mm3, ANC &gt;1.500/ mm3, platelet (PLT) count (ct) &gt;100.000/ mm3, hemoglobin (Hgb) concentration &gt;11 g/dL (untransfused), bone marrow (BM) lymphocytosis &lt;30%, and no nodules (lymphoid aggregates) on BM biopsy. Partial Response (PR): present &gt;=2 months: a reduction in prev. enlarged nodes, spleen, &amp; liver by at least 50%. ANC &gt;= 1.500/ mm3 or PLT ct &gt;= 100.000/ mm3 or Hgb concentration &gt;=11 g/dL or 50% improvement over pre-therapy reductions in Hgb concentration and/or PLT ct. Nodular PR: persistent BM nodules or infiltrates seen on BM biopsy those achieving a CR or PR. Stable Disease (SD): Does not meet CR or PR, but also not progressive disease (PD). PD: 50% size increase of lymph node, spleen, liver; or histologic (e.g. Richter's) transformation (per NCI and iwCLL).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response with Lymphocytosis (PR-L)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Kaplan-Meier method will be used to estimate the survival curve.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Given the significant evolution of the treatment landscape, overall survival was no longer deemed to be a worthwhile/meaningful endpoint. Patients were lost to follow up and data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Dasatinib)</title>
            <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Kaplan-Meier method will be used to estimate the survival curve.</description>
          <population>Given the significant evolution of the treatment landscape, overall survival was no longer deemed to be a worthwhile/meaningful endpoint. Patients were lost to follow up and data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Kaplan-Meier method will be used to estimate the survival curve.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Given the significant evolution of the treatment landscape, overall survival was no longer deemed to be a worthwhile/meaningful endpoint. Patients were lost to follow up and data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Dasatinib)</title>
            <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Kaplan-Meier method will be used to estimate the survival curve.</description>
          <population>Given the significant evolution of the treatment landscape, overall survival was no longer deemed to be a worthwhile/meaningful endpoint. Patients were lost to follow up and data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (Number of Participants Affected)</title>
        <description>Assessed According to the NCI Common Terminology Criteria for Adverse Events Version 4.0. Adverse events will be tabulated and summarized according to key reporting criteria (i.e., grade or seriousness, unanticipated, treatment attribution). Refer to the Adverse Event tables below for specific details.</description>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Dasatinib)</title>
            <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (Number of Participants Affected)</title>
          <description>Assessed According to the NCI Common Terminology Criteria for Adverse Events Version 4.0. Adverse events will be tabulated and summarized according to key reporting criteria (i.e., grade or seriousness, unanticipated, treatment attribution). Refer to the Adverse Event tables below for specific details.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected within 30 days of discontinuation of study drug, up to 4 years.</time_frame>
      <desc>Adverse events were tabulated and summarized according to key reporting criteria (i.e., grade or seriousness, unanticipated, treatment attribution).</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Dasatinib)</title>
          <description>Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Dasatinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE V4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Grade 3 Edema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilateral leg edema</sub_title>
                <description>Grade 3 leg edema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>Grade 3 leukocytosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 3 thrombocytopenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3 neutropenia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 3 Anemia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Grade 3 hyperkalemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Grade 3 conjunctivitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Grade 3 Colitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Grade 3 Fatigue</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>vasovagal reaction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Grade 3 vasovagal reaction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Grade 3 organizing pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Grade 3 hypocalcemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Swelling</sub_title>
                <description>Grade 3 Facial swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>basal cell carcinoma</sub_title>
                <description>Grade 3 basal cell carcinoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations or caveats are noted at this time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stephen Spurgeon</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-4606</phone>
      <email>spurgeos@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

